Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Geneos Wealth Management Inc. purchased a new stake in shares of GSK plc (NYSE:GSK – Free Report) during the fourth quarter, ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

one has issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, GSK currently has a consensus rating of “Moderate Buy” and a consensus price ...

GSK share price remains in a deep bear market after falling by 21% ... pressure in the past few months as investors watch the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Two FTSE 100 stocks in Harvey Jones' portfolio have suffered double-digit losses. He's standing by them for now, but he's ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This Fool considers how two low-risk and well-established FTSE shares could offer stability and growth during a period of market volatility.